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suspected soft tissue disorders, or osteoarthritis (73.0–
85.3 %). In RA patients, 56.3 % of examinations were 
conducted to monitor disease activity. Nearly all investiga-
tions (99 %) had clinical implications, while the results of 
78.6 % of examinations (51.6–99.0 %) were deemed useful 
for patient education. This first standardized multicountry 
survey performed in CEEs provided a structured documen-
tation of the routine MSUS use in participating countries. 
The majority of MSUS examinations were performed for 
diagnostic purposes, whereas one-third was conducted to 
monitor disease activity in RA. A majority of examinations 
had an impact on clinical decision making and were also 
found to be useful for patient education.
Keywords Ultrasonography · Musculoskeletal ·  
Central-Eastern Europe · Clinical practice · Education
Abstract The main aim was to gain structured insight 
into the use of musculoskeletal ultrasonography (MSUS) 
in routine rheumatology practices in Central and Eastern 
European (CEE) countries. In a cross-sectional, observa-
tional, international, multicenter survey, a questionnaire 
was sent to investigational sites in CEE countries. Data on 
all subsequent routine MSUS examinations, site character-
istics, MSUS equipment, and investigators were collected 
over 6 months or up to 100 examinations per center. A total 
of 95 physicians at 44 sites in 9 countries provided infor-
mation on a total of 2810 MSUS examinations. The most 
frequent diagnoses were rheumatoid arthritis (RA) and 
spondyloarthritis (34.8 and 14.9 % of cases, respectively). 
Mean number of joints examined was 6.8. MSUS was 
most frequently performed for diagnostic purposes (58 %), 
particularly in patients with undifferentiated arthritis, 
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Introduction
In the past decade, musculoskeletal ultrasonography 
(MSUS) has been extensively used by an ever-growing 
number of rheumatologists in both research studies as well 
as in daily clinical practice. The need to monitor individual 
patients, along with the recognition that MSUS can depict 
subclinical synovitis and enthesitis, have been the main 
drivers behind the escalating utilization of MSUS [1–4]. 
In addition, MSUS has the potential to reliably guide treat-
ment interventions (e.g., needle aspiration, intra-articular 
injections) [5, 6] and was shown to have profound effects 
on disease classification and physician decision making [7, 
8]. Progress in practice was accompanied by an increasing 
need for organized education regarding the use of MSUS 
[6, 9, 10]. European guidelines for education and documen-
tation of MSUS for rheumatologists, including those issued 
by the European Federation of Societies of Ultrasound in 
Medicine and Biology were issued [10–12]. Advancements 
in research and education were accompanied by increas-
ing access to MSUS devices among rheumatologists [13]. 
Nowadays, an increasing number of hospital departments, 
outpatient clinics, and emergency departments equip 
their facilities with ultrasound devices suitable for MSUS 
imaging.
Most of the available data on MSUS in the field of 
rheumatology has been collected within the framework of 
clinical studies. Data on the actual usage and utilization 
of MSUS equipment in routine clinical practice by rheu-
matologists in Europe, however, are limited and outdated. 
The few available surveys collected information primar-
ily on the expertise and training of the investigators, rather 
than on the MSUS examinations themselves [6, 9, 14]. 
Detailed analysis of such examinations would be particu-
larly relevant for improving MSUS utilization and value in 
general and could facilitate ongoing international research 
activities. Such data are particularly lacking for Central and 
Eastern Europe, a region in which we know almost nothing 
about the overall acceptance of MSUS in rheumatologic 
practice.
The primary objective of the Musculoskeletal Ultra-
Sound as a Tool (MUST) study was to gain insight into 
the use of MSUS imaging in routine rheumatologic care in 
Central and Eastern European (CEE) countries.
Methods
This cross-sectional, observational, multicenter survey was 
conducted in the following nine CEE countries: Bulgaria, 
Croatia, the Czech Republic, Estonia, Hungary, Lithuania, 
Romania, the Republic of Serbia, and the Slovak Repub-
lic. From the remaining countries in the CEE region, 
representatives from Albania, Latvia, Poland, and Slove-
nia were contacted by the principal investigators; however, 
these countries declined to participate in the study. Monte-
negro, Macedonia, Kosovo, and Bosnia–Herzegovina were 
omitted because of the absence of country representation 
with regard to the study sponsor (AbbVie).
Investigational sites were selected based on the avail-
ability of MSUS equipment at the site and were identified 
with help from the national societies to ensure representa-
tive coverage in each individual country. The aim was to 
collect approximately 3000 data sets from approximately 
40–50 sites.
Participating sites recorded information on the method-
ology of all consecutive MSUS examinations performed 
over a 6-month period or up to 100 ultrasonography events, 
regardless of diagnosis, extent, location, or purpose of 
MSUS imaging. Data for site and investigator charac-
teristics were recorded by using purpose-designed case 
report forms (CRFs) in English. Additional CRFs were 
used for capturing information about the individual MSUS 
examinations.
The following endpoints were investigated: frequency 
of MSUS imaging at study sites; the percentage of MSUS 
examinations performed at various stages of individual 
disorders; the purpose of MSUS imaging; and the impact 
of MSUS findings on clinical decision making and on the 
professional conduct of the investigator. Furthermore, the 
study gathered information on the study site, ultrasound 
equipment, number of rheumatologists, and their level of 
competence in diagnostic MSUS, as well as on patient 
turnover at individual sites.
For the statistical analysis, three analysis sets were uti-
lized: (1) a site-based analysis set (SBS), which included 
all data on participating study sites documenting at least 
1 MSUS investigation; (2) an investigator-based analysis 
set (IBS), including all data on MSUS investigators at par-
ticipating study sites (i.e., those included in the SBS); and 
(3) an examination-based analysis set (EBS), comprised of 
data on all documented MSUS investigations.
The study was approved by the appropriate national eth-
ics committees in each participating CEE country. Study-
related activities started only after informed consent was 
obtained from the patients.
The statistical analyses were carried out with version 9.2 
of Statistical Analysis System software (SAS Institute Inc., 
Cary, NC, USA). Data were stratified according to study 
site, investigator, and type of examination. Simple descrip-
tive and summary statistics were calculated. Qualitative 
data (e.g., gender) were generally presented as frequency 
distributions. For the calculation of percentages, missing 
data (denoting data not entered into the CRF) were gener-
ally considered as a separate group. Quantitative data (e.g., 
age) were analyzed by statistical parameters such as valid 
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N, mean, standard deviation (SD), minimum, maximum, 
and median. Where applicable and interpretable, 95 % con-
fidence intervals (CIs) are provided. All analyses were gen-
erally performed overall and by country.
Results
MSUS sites (SBS analysis)
Data were collected on 2810 MSUS examinations per-
formed by 95 rheumatologists at 44 study sites in nine CEE 
countries, during the observation period from July 2011 to 
October 2012. The number of sites included for each coun-
try was as follows: Romania, ten sites; Bulgaria, eight sites; 
Hungary and Czech Republic, six sites each; Slovakia, four 
sites; Estonia and Croatia, three sites each; and Lithuania 
and Serbia, two sites each.
The majority of sites were either university hospitals (25 
sites; 56.8 %) or other hospitals (11 sites; 25.0 %), while 
seven additional centers included private practices (4 sites; 
9.1 %), outpatient clinics (1 site; 2.3 %), and other medical 
institutions (2 sites; 4.5 %). These data were missing for a 
single site (2.3 %).
Annual turnover of rheumatology patients undergo-
ing MSUS was between 1000 and 10,000 in the majority 
(68.2 %) of study sites. The largest data sets were reported 
from Hungarian (546 MSUS examinations), Romanian 
(500 MSUS examinations), and Estonian (351 MSUS 
examinations) sites. A mean of 4.6 ± 3.3 (SD) MSUS 
examinations were carried out weekly at these sites, with 
the lowest mean of 1.5 ± 1.6 examinations in Bulgaria and 
the highest mean of 9.0 ± 3.6 examinations in Lithuania.
Over all study sites, on average, 3.7 ± 2.6 physi-
cians were trained in the application of MSUS. The mean 
number of trained rheumatologists was highest in Serbia 
(6.5 ± 2.1) and lowest in Slovakia (2.0 ± 0.8). The major-
ity of the rheumatologist experts undertook either any one 
of the official EULAR MSUS courses (beginner, interme-
diate or advanced) or EULAR-endorsed MSUS courses, 
while a smaller number undertook national courses.
The brand and type of MSUS equipment varied between 
(and in some cases within) each CEE country. Information 
on the major brands and type of MSUS equipment within 
the CEE region, along with the transducer frequencies, is 
provided in Supplementary Table 1.
MSUS investigators (IBS analysis)
MSUS investigators carried out a mean number of 
29.6 ± 18.5 MSUS weekly examinations, ranging from 
a mean of 8.7 ± 3.4 examinations in Bulgaria to up to 
60.0 ± 22.4 examinations in Serbia. The mean number of 
MSUS courses attended by the rheumatologist investiga-
tors was 2.9 ± 2.3. On average, physicians in the Serbian 
study sites attended the highest number of MSUS courses, 
with a mean number of 8.3 ± 4.6, whereas physicians in 
Lithuania attended only 1.5 ± 0.6 courses. Every second 
physician (n = 49; 51.6 %) attended at least one advanced 
level MSUS course, while 39 (41.1 %) attended at least one 
basic level course.
MSUS examinations (EBS analysis)
Scheduling of the MSUS examinations
Most MSUS examinations (51.9 %) were scheduled ad 
hoc, whereas 43.4 % of examinations were elective. While 
the rate of ad hoc investigations was highest in Lithuania 
(76.3 %) and lowest in Bulgaria (20.4 %), elective exami-
nations were most frequent in Croatia (65.0 %) and least 
frequent in Lithuania (17.7 %). The majority of examina-
tions were initial investigations (79.6 %), whereas only 
18.3 % were repeated. In Hungary, the rate of initial exami-
nations was highest at 88.5 % (and lowest with 9.9 % of 
repeated investigations); in Bulgaria, the rates were 55.8 % 
(initial) and 42.5 % (repeated).
Diseases assessed with the MSUS examinations
The most common diagnosis within this study was rheu-
matoid arthritis (RA), which was diagnosed in 34.8 % of 
the examined patients (Table 1). Other common diagnoses 
included spondyloarthritis (SpA; 14.9 %), soft tissue disor-
ders (14.7 %), osteoarthritis (OA; 12.9 %) and undifferen-
tiated arthritis (UA; 10.9 %); all other diagnoses [juvenile 
idiopathic arthritis, gout, calcium pyrophosphate dehy-
drate (CPPD) deposition disease, septic arthritis, and sys-
temic lupus erythematosus] represented <10 % of patients. 
Nearly every second patient (51.9 %) was classified as hav-
ing chronic disease at the time of the MSUS examination.
Content of the MSUS examinations
Investigated structures were mostly joints (93.3 %); in 
15.1 % of cases, entheses were examined, while the exami-
nation included other soft tissue structures in 23.0 % of 
examinations. The percentage of examinations investigat-
ing joints was relatively homogeneous between the differ-
ent CEE countries (88.6–98.7 %); however, entheses were 
examined in only 6.8 % of MSUS examinations in Hun-
gary, while 37.2 % were examined in Bulgaria.
The number of joints investigated per MSUS exami-
nation ranged between 1 and 46 joints, with a mean of 
6.8 ± 8.4 joints. The highest mean number of investi-
gated joints was reported in patients with RA (9.8 ± 9.4), 
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followed by patients with unknown or missing diagnosis 
(9.4 ± 10.3). The fewest number of joints was reported for 
septic arthritis (1.3 ± 0.5). Similarly, the number of enthe-
ses ranged from 1 to 40, with a mean of 3.6 ± 3.5 entheses.
Purpose of the MSUS examinations
The majority of MSUS examinations (58.8 %) had a diag-
nostic purpose, while 33.2 and 15.0 % of examinations 
were performed to monitor disease activity or the effi-
cacy of treatment, respectively. Guidance of an interven-
tional procedure served as a purpose in 11.6 % of MSUS 
examinations. The highest rate of diagnostic investiga-
tions occurred in Lithuania (74.7 %), whereas the lowest 
occurred in Bulgaria (47.8 %). The proportion of exami-
nations monitoring disease activity ranged from 9.3 % in 
Serbia to 49.4 % in Romania. The purpose of MSUS for 
monitoring treatment efficacy ranged from 7.3 % in Croatia 
to 35.4 % in Bulgaria and the use of MSUS to aid in an 
interventional procedure ranged from 0.3 % in Croatia to 
22.8 % in Estonia. In 0.4 % of cases, the respective infor-
mation was missing.
The purpose of the MSUS examinations differed 
between the different rheumatic diseases. While the major-
ity of MSUS examinations (56.3 %) in patients with RA 
were performed for the purpose of monitoring disease 
activity, in patients with UA, as well as in those with sus-
pected soft tissue disorders or OA, the MSUS examina-
tion primarily served a diagnostic purpose (82.0, 85.3, and 
73.0 %, respectively; Table 2). In patients with SpA, the 
ratio between diagnostic and monitoring examinations was 
balanced (46.3 and 42.0 %, respectively).
Impact of the MSUS examinations
In almost all cases, the MSUS examinations had at least 
some impact, with no impact implicated in only 28 cases 
(1.0 %). In 58.6 % of cases, the results of the examina-
tion confirmed a clinical suspicion; in 24.9 % of cases, 
it clarified an unclear pathology; in 23.6 % of cases, the 
Table 1  MSUS examinations 
grouped by the most common 
diagnoses
n number of MSUS examinations, % percentage of MSUS examinations by the individual diagnoses, 
CPPD calcium pyrophosphate dehydrate deposition disease, JIA juvenile idiopathic arthritis, OA osteoar-
thritis, MSUS musculoskeletal ultrasonography, RA rheumatoid arthritis, SA septic arthritis, SLE systemic 
lupus erythematosus, SpA spondyloarthritis, UA undifferentiated arthritis
Country RA SpA Soft tissue  
disorder
OA UA
n % n % n % n % n %
Bulgaria 48 42.5 37 32.7 8 7.1 5 4.4 1 0.9
Czech Republic 75 37.5 45 22.5 20 10.0 18 9.0 25 12.5
Croatia 105 35.0 41 13.6 56 18.7 24 8.0 42 14.0
Estonia 94 26.8 72 20.5 58 16.5 47 13.4 35 10.0
Hungary 201 36.8 64 12.3 91 16.7 65 11.9 60 11.0
Lithuania 82 27.3 38 12.6 31 10.3 17 5.7 67 22.3
Romania 212 42.4 63 12.6 80 16.0 57 11.4 37 7.4
Serbia 54 18.0 15 5.1 64 21.3 113 37.7 30 10.0
Slovakia 107 53.5 41 20.5 6 3.0 17 8.5 8 4.0
Total 978 34.8 419 14.9 414 14.7 363 12.9 305 10.9
Country Gout JIA CPPD SA SLE
n % n % n % n % n %
Bulgaria 9 8.0 0 0.0 5 4.4 0 0.0 0 0.0
Czech Republic 7 3.5 6 3.0 0 0.0 0 0.0 1 0.5
Croatia 9 3.0 3 1.0 3 1.0 1 0.3 6 2.0
Estonia 16 4.6 11 3.1 6 1.7 0 0.0 3 0.9
Hungary 11 2.0 26 4.8 10 1.8 4 0.7 5 0.9
Lithuania 19 6.3 8 2.7 3 1.0 16 5.3 3 1.0
Romania 33 6.6 2 0.4 10 2.0 5 1.0 7 1.4
Serbia 9 3.0 0 0.0 3 1.0 0 0.0 0 0.0
Slovakia 2 1.0 4 4.0 1 0.5 2 1.0 3 1.5
Total 115 4.1 60 2.1 41 1.5 28 1.0 28 1.0
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examination resulted in change in treatment; in 14.7 % of 
cases, it revealed information that was different from the 
clinical investigation; and in 10.1 % of cases, it helped 
established a new diagnosis (Table 3).
Based on their reports, overall, the investigators consid-
ered the MSUS examination to be a reasonable use of their 
time in the vast majority of cases (96.6 %; Table 4). Inves-
tigators in Serbia showed considerably divergent assess-
ments from the other countries in this context, with only 
83.3 % of examinations classified as reasonable.
The results of 87.0 % of MSUS examinations were 
found to have educational value for the physician, while 
the results of only 11.8 % of examinations had no educa-
tional value for the physician (Table 5). Again, the lowest 
rate of positive assessment in this regard was observed in 
Serbia, with an educational value attributed to only 67.3 % 
of investigations.
Every third MSUS examination (33.3 %) was reported 
as not useful for teaching or sharing purposes (i.e., with 
colleagues), whereas in 65.1 % of cases, rheumatologists 
were able to utilize the results for either one of the afore-
mentioned purposes. In 78.6 % of examinations, the results 
were used to educate the patient (Table 6). The highest and 
lowest rates (99.0 and 51.6 %) in this regard were observed 
in Slovakia and Estonia, respectively. In 2.5 % of examina-
tions, information about the potential educational value for 
the patient was missing.
Discussion
This is the first study that provides comparative informa-
tion about real-life MSUS examinations in routine rheu-
matologic care in CEE countries based on a structured 
questionnaire.
In recent years, MSUS has established itself as a highly 
sensitive and useful diagnostic tool for the detection of 
intra- and periarticular changes, including synovitis, 
tenosynovitis, bone erosions, and osteophytes, which are 
pivotal to most commonly occurring rheumatic diseases 
[15–19]. Reflecting this progress, MSUS is now a recom-
mended imaging modality for diagnostic, monitoring, and 
predictive purposes with both RA and SpA [20, 21]. The 
data supporting such applications of MSUS in daily clini-
cal practice are derived almost exclusively from observa-
tional studies. The vast majority of these studies, however, 
included selected patients, highly trained observers, as 
well as high-end ultrasound equipment. Information on the 
actual usage of MSUS in routine care is scarce to nonexist-
ent, and was primarily assessed on a national level [22–28]. 
European surveys have reported considerable variation in 
training and practice between countries for both MSUS 
examinations in general and ultrasound-guided musculo-
skeletal interventions [6, 9, 14]. Rather than analyzing the 
standardized documentation of routine MSUS examina-
tions, the available studies evaluated the needs and prac-
tice of participants (rheumatologists and/or rheumatologist 
experts in MSUS) [6, 9, 14, 22–29]. Therefore, it is difficult 
to draw comparisons between the findings of these studies 
and our study, which was based on the standardized docu-
mentation of routine MSUS examinations. Broadly speak-
ing the main findings of our study are in accordance with 
other studies. In their study on the use of MSUS in the UK, 
Brown et al. [24] have found that the greatest clinical util-
ity of MSUS were inflammatory arthritis assessment and 
guided procedures, findings which were also verified by 
Cunnington et al. [25]. Similarly to our study, a Romanian 
and a Spanish study could demonstrate that MSUS was pri-
marily used as for diagnostic and monitoring purposes [27, 
28].
Our survey, based on the standardized documentation of 
routine MSUS examinations, confirmed that MSUS is uti-
lized in daily clinical practice in CEE countries. Overall, 
MSUS is primarily used to monitor RA, while it is utilized 
as a diagnostic tool in other commonly occurring rheuma-
tologic diseases, such as OA or UA. We found that MSUS 
Table 2  Purpose of MSUS 
examinations grouped by the 
most common diagnoses
Multiple choice was possible
n number of MSUS examinations, % percentage of MSUS examinations by the individual diagnoses, 
MSUS musculoskeletal ultrasonography, OA osteoarthritis, RA rheumatoid arthritis, SpA spondyloarthritis, 
UA undifferentiated arthritis






n % n % n % n %
RA 356 36.4 551 56.3 252 25.8 85 8.7
SpA 194 46.3 176 42.0 79 18.9 51 12.2
Soft tissue disorders 353 85.3 35 8.5 23 5.6 64 15.5
OA 265 73.0 43 11.8 24 6.6 81 22.3
UA 250 82.0 44 14.4 16 5.2 24 7.9
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Table 3  Impact of MSUS 
examinations
Multiple choice was possible




















n % n % n % n % n % n %
Bulgaria 79 69.9 9 8.0 9 8.0 5 4.4 35 31.0 17 15.0
Czech Republic 116 58.0 34 17.0 20 10.0 3 1.5 34 17.0 18 9.0
Croatia 147 49.0 49 16.3 47 15.7 16 5.3 120 40.0 18 6.0
Estonia 196 55.8 59 16.8 28 8.0 9 2.6 28 8.0 9 2.6
Hungary 349 63.9 50 9.2 32 5.9 7 1.3 117 21.4 34 6.2
Lithuania 117 39.0 49 16.3 22 7.3 14 4.7 96 32.0 19 6.3
Romania 304 60.8 78 15.6 80 16.0 7 1.4 169 33.8 55 11.0
Serbia 196 65.3 70 23.3 34 11.3 45 15.0 58 19.3 5 1.7
Slovakia 144 72.0 16 8.0 13 6.5 4 2.0 43 21.5 22 11.0











Other impact No 
impact
n % n % n % n % n % n %
Bulgaria 35 31.0 9 8.0 65 57.5 6 5.3 7 6.2 0 0.0
Czech Republic 7 3.5 2 1.0 42 21.0 4 2.0 14 7.0 1 0.5
Croatia 22 7.3 17 5.7 53 17.7 16 5.3 2 0.7 3 1.0
Estonia 17 4.8 12 3.4 71 20.2 8 2.3 53 15.1 5 1.4
Hungary 42 7.7 5 0.9 104 19.0 30 5.5 23 4.2 3 0.5
Lithuania 20 6.7 22 7.3 84 28.0 30 10.0 3 1.0 2 0.7
Romania 75 15.0 8 1.6 141 28.2 19 3.8 41 8.2 7 1.4
Serbia 10 3.3 14 4.7 61 20.3 10 3.3 3 1.0 5 1.7
Slovakia 16 8.0 2 1.0 43 21.5 10 5.0 0 0.0 2 1.0
Total 244 8.7 91 3.2 664 23.6 133 4.7 146 5.2 28 1.0
Table 4  MSUS as a reasonable 
use of time
n number of US examinations, % percentage of US examinations within the respective country, MSUS 
musculoskeletal ultrasonography
Country Reasonable Not reasonable Missing Total
n % n % n % n %
Bulgaria 112 99.1 0 0.0 1 0.9 113 100.0
Czech Republic 200 100.0 0 0.0 0 0.0 200 100.0
Croatia 290 96.7 9 3.0 1 0.3 300 100.0
Estonia 325 92.6 8 2.3 18 5.1 351 100.0
Hungary 542 99.3 3 0.5 1 0.2 546 100.0
Lithuania 298 99.3 0 0.0 2 0.7 300 100.0
Romania 498 99.6 2 0.4 0 0.0 500 100.0
Serbia 250 83.3 50 16.7 0 0.0 300 100.0
Slovakia 199 99.5 1 0.5 0 0.0 200 100.0
Total 2714 96.6 73 2.6 23 0.8 2810 100.0
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was also frequently utilized in the diagnosis of soft tissue 
disorders; this latter finding likely reflects an unmet diag-
nostic need. Consequently, MSUS was likely underutilized 
for other connective tissue diseases, such as systemic lupus 
erythematosus, in which the diagnosis of musculoskel-
etal imaging in general plays a smaller role. The number 
of examined joints was also highest in RA, likely reflect-
ing its polyarticular involvement as compared to the other 
conditions. The fact that MSUS examination most com-
monly led to the establishment of a new diagnosis in CPPD 
deposition disease is in agreement with studies that suggest 
that MSUS might prove to be a sensitive and specific tool 
for the diagnosis of CPPD crystal arthritis and may even 
outperform conventional X-ray imaging [30, 31]. The fact 
that the percentage of MSUS examinations performed to 
guide musculoskeletal procedures (i.e., joint and soft tissue 
injections, arthrocentesis, or biopsies) was relatively lower 
for inflammatory arthritides (RA, SpA, and UA) and higher 
for OA and soft tissue disorders might reflect the different 
role and weight of local interventions within the therapeu-
tic armamentarium for the given conditions.
While we provide novel insights, our study has some 
limitations. Although nine countries contributed valuable 
data to the MUST survey, eight additional CEE countries 
declined or were unable to participate. The overwhelming 
majority of study centers were university or other hos-
pitals. The extent of possible differences in the routine 
practices of the individual study sites is also unknown. 
The MSUS equipment and competence of profession-
als who participated in the survey also varied consider-
ably between countries and sites. While investigators in 
the participating centers were requested to document and 
Table 5  General educational 
effect of MSUS
n number of US examinations, %, percentage of US examinations within the respective country, MSUS 
musculoskeletal ultrasonography
Country Educational value for physician Missing data Total
Yes No
n % n % n % n %
Bulgaria 101 89.4 9 8.0 3 2.7 113 100.0
Czech Republic 184 92.0 16 8.0 0 0.0 200 100.0
Croatia 292 97.3 8 2.7 0 0.0 300 100.0
Estonia 254 72.4 79 22.5 18 5.1 351 100.0
Hungary 469 85.9 76 13.9 1 0.2 546 100.0
Lithuania 278 92.7 12 4.0 10 3.3 300 100.0
Romania 468 93.6 32 6.4 0 0.0 500 100.0
Serbia 202 67.3 96 32.0 2 0.7 300 100.0
Slovakia 197 98.5 3 1.5 0 0.0 200 100.0
Total 2445 87.0 331 11.8 34 1.2 2810 100.0
Table 6  The MSUS 
examination as a tool for patient 
education
n number of US examinations, %, percentage of US examinations within the respective country, MSUS 
musculoskeletal ultrasonography
Country Educational purpose Non-educational 
purpose
Missing data Total
n % n % n % n %
Bulgaria 103 91.2 9 8.0 1 0.9 113 100.0
Czech Republic 168 84.0 32 16.0 0 0.0 200 100.0
Croatia 287 95.7 13 4.3 0 0.0 300 100.0
Estonia 181 51.6 140 39.9 30 8.5 351 100.0
Hungary 406 74.4 140 25.6 0 0.0 546 100.0
Lithuania 216 72.0 46 15.3 38 12.7 300 100.0
Romania 420 84.0 80 16.0 0 0.0 500 100.0
Serbia 231 77.0 68 22.7 1 0.3 300 100.0
Slovakia 198 99.0 2 1.0 0 0.0 200 100.0
Total 2210 78.6 530 18.9 70 2.5 2810 100.0
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report all and every MSUS examination conducted within 
the study period, we cannot rule out sampling bias intro-
duced by the individual investigators. However, given the 
multinational and multicenter nature of our survey, the 
influence of such biases, if any, is negligible. Addition-
ally, inherent survey bias may have led to overestimation, 
in particular with regard to the reasonable use of time 
and educational value. Also with regard to the latter data 
and also with regard to the clinical impact of the MSUS 
examination, our findings are based simply on the physi-
cian’s response and may have introduced a certain partici-
pation bias, which, however, certainly applies to almost 
all studies conducted among rheumatologists practicing 
MSUS. Nevertheless, this does limit the applicability of 
our results to rheumatologists in general and likely rep-
resents the views of rheumatologist experts in MSUS 
predominantly.
When considering the common diagnoses, which were 
examined by MSUS, the overall case mix of the study 
centers should also be taken into account; however, such 
data were not collected within the framework of the study. 
Finally, lacking comparable multicenter studies, no refer-
ence exists to compare our data with that of other regions 
of the world.
Overall, we have shown that MSUS may play an impor-
tant role in the diagnosis and monitoring of commonly 
occurring rheumatic diseases, as well as on therapeutic 
decision making in CEE countries. MSUS is considered 
to be a reasonable use of time and has educational value 
for both physicians and patients. These results and the dif-
ferences among the surveyed countries suggest a need to 
develop a more comprehensive international guideline for 
the extension of the use of MSUS in view of the current 
practices in rheumatology.
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